AVITA Medical, Inc. (RCEL) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 4 Buy, 3 Hold.
The consensus price target is $3.50, representing a downside of 32.2% from the current price $5.16.
Analysts estimate Earnings Per Share (EPS) of $-2.26 and revenue of $0.07B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.39 vs est $-2.26 (missed -5.9%). 2025: actual $-1.74 vs est $-1.71 (missed -1.5%). Analyst accuracy: 96%.
RCEL Stock — 12-Month Price Forecast
$3.50
▼ -32.17% Downside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for AVITA Medical, Inc., the price target is $3.50.
The average price target represents a -32.17% change from the last price of $5.16.
RCEL Analyst Ratings
Buy
Based on 7 analysts giving stock ratings to AVITA Medical, Inc. in the past 3 months
EPS Estimates — RCEL
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.39
vs Est –$2.26
▼ 5.6% off
2025
Actual –$1.74
vs Est –$1.71
▼ 1.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — RCEL
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.064B
vs Est $0.067B
▼ 3.5% off
2025
Actual $0.072B
vs Est $0.071B
▲ 0.2% off
Revenue Trend
Moderate revenue growth trend. Analysts expect stable revenue going forward.
